F-star Therapeutics EBIT

F-star Therapeutics's ebit stands at $-37M as of September 2022. That compares with $-45M in the prior-year period — up 17.7% year over year. That is below the Healthcare sector average of $22B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

F-star Therapeutics reported $-37M in EBIT versus $-45M a year earlier — a 17.7% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

F-star Therapeutics sits lower the Healthcare benchmark ($22B) with a EBIT of $-37M. That is roughly 100.2% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $-45M in the prior-year period — up 17.7% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how F-star Therapeutics's EBIT evolved across reporting periods, while the comparison chart places FSTX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.